Objectif de l'étude : This phase II trial investigates the efficacy and safety of dabrafenib and trametinib treatment in patients with Erdheim Chester disease that have BRAF V600 gene mutations.
Parrain : National Cancer Institute (NCI)
Coordonnées pour l'essai : Study Coordinator: Ms. Abha Adat, aadat@mdanderson.org, or the Principal Investigator Filip Janku, 713-563-1930, FJanku@mdanderson.org.
Participation demandée au patient : ECD patients with BRAF V600 mutation who have not previously been treated with a BRAF- or MEK-inhibitor and are 18-years or older.
Centres connus acceptant des patients atteints d'ECD dans le cadre de l'essai : MD Anderson, Houston, Texas
Identifiant ClinicalTrials.gov : NCT03794297

